Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced that its Phase 2 trial for ETD001, the Company's lead candidate for treatment of cystic fibrosis (CF), achieved its primary efficacy outcome.

From Enterprise Therapeutics Ltd 12 May 2026

Qureight establishes Scientific Advisory Board focused on pulmonary hypertension

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has established a Scientific Advisory Board (SAB) focused on pulmonary hypertension (PH).

From Qureight 11 May 2026

Study reveals immune differences between titanium and zirconia implants

Zirconia is widely regarded as a promising alternative to titanium for bone and dental implants because of its aesthetic advantages, biocompatibility, and potential to reduce metal ion release.

10 May 2026

Asthma medication formoterol shows promise for treating fatty liver disease

MUSC researchers are tackling MASH, or metabolic dysfunction-associated steatohepatitis, a liver disease affecting hundreds of millions worldwide.

8 May 2026

New ‘heart-on-a-chip’ to halt cardiac damage caused by Duchenne

Duchenne Parent Project Spain (DPPE) has launched the BEAT Project, a research initiative focused on one of the key challenges associated with Duchenne and Becker muscular dystrophies: progressive heart damage. Cardiomyopathy is the leading cause of death in patients with DMD.

7 May 2026

KIF13B protects heart function during sepsis by regulating lipid metabolism

Sepsis, a life-threatening condition caused by dysregulated host response to infection, remains a major cause of global mortality.

5 May 2026

New research shows weight loss is possible without GLP-1

Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.

30 Apr 2026

Cells filter physical forces based on duration to detect disease

Scientists have discovered how cells decide when to respond to physical forces, potentially opening new avenues for tackling diseases such as cancer and fibrosis.

29 Apr 2026

Lung scan patterns predict severity of sarcoidosis and breathing issues

A new study from researchers at National Jewish Health and collaborating institutions has found that different patterns seen on lung scans can signal how severe sarcoidosis may be, and how it affects breathing.

28 Apr 2026

Virginia Tech team identifies proteins that can reverse lung scarring

A Virginia Tech team has identified a promising new therapeutic strategy for idiopathic pulmonary fibrosis (IPF), showing that blocking two proteins can halt and even reverse lung scarring in pre-clinical models.

28 Apr 2026

Biliary epithelial cells found to actively prevent liver fibrosis development

Many liver diseases share a common characteristic: fibrosis, that is, the progressive accumulation of scarring in the liver tissue.

28 Apr 2026

Natural compound obakulactone shows therapeutic potential for rheumatoid arthritis

A new study published in Engineering reveals that obakulactone (OL), a natural tetracyclic triterpenoid isolated from Phellodendri cortex, exerts a therapeutic effect on rheumatoid arthritis (RA) by promoting the degradation of acyl coenzyme A thioesterase 1 (ACOT1) via the ubiquitin‒proteasome pathway and restoring the homeostasis of unsaturated fatty acids.

25 Apr 2026

Researchers pioneer breakthrough therapy for life-threatening infections

A revelatory treatment for patients with life-threatening infectious diseases is being pioneered in Melbourne by researchers at The Alfred and Monash University.

25 Apr 2026

Fucosylated IgG drives adipose tissue dysfunction during aging

A study published in Engineering has identified fucosylated immunoglobulin G (IgG) as a key mediator contributing to adipose tissue dysfunction during aging, offering insights into age-related metabolic disorders and potential therapeutic targets.

25 Apr 2026

Losing weight improves heart muscle contraction in people with obesity and heart failure

In a new research report, a team of scientists led by Johns Hopkins Medicine say people with severe obesity and a common type of heart failure experience weakened heart muscles, and that losing weight may reverse some of these effects.

25 Apr 2026

Exploiting a new weakness in 'zombie-like' cells to treat senescence-associated diseases

A new set of drugs exploit a recently-revealed weakness in 'zombie-like' – or senescent – cells that could lead to new treatments for cancer and age-associated diseases.

24 Apr 2026

Specific intestinal fungi play role in the pathogenesis of MASLD and cardiovascular disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an independent risk factor for cardiovascular disease (CVD). While gut bacteria have been linked to CVD, the role of intestinal fungi in subclinical coronary atherosclerosis (SCA) remains unclear.

23 Apr 2026